Following a full submission
Bivalirudin (Angiox) is accepted for restricted use within NHS Scotland as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA) procedures like angioplasty and balloon angioplasty and PTCA with stenting.
It is restricted to patients who would have been considered for treatment with unfractionated heparin in combination with a glycoprotein llb/llla antagonist. In these patients bivalirudin monotherapy may be a suitable alternative. It should not be used as an alternative to unfractionated heparin alone.
Download detailed advice89KB (PDF)
- Medicine name:
- Bivalirudin 250mg for injection or infusion (Angiox®)
- SMC ID:
- Anticoagulant in patients undergoing percutaneous coronary intervention
- Pharmaceutical company
- Nycomed UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Date advice published
- 07 March 2005